Group 1 - The company, Renhe Pharmaceutical, has prioritized the supply of key medications such as Oseltamivir Phosphate, Ibuprofen, and Compound Paracetamol and Amantadine Capsules in response to high market demand [1]

Core Viewpoint - The company, Renhe Pharmaceutical, confirmed the availability of several influenza treatment medications and emphasized its commitment to ensuring stable production and supply to meet market demand [2]. Product Information - The company currently sells influenza treatment medications including Oseltamivir Phosphate Capsules, Ibuprofen Sustained-Release Capsules, Amoxicillin Capsules, Compound Aminophenol and Amantadine Capsules, Strong Loquat Capsules, and Pediatric Acetaminophen Granules [2]. - In addition to these, the company offers various medications for symptoms related to influenza-like illnesses, providing consumers with multiple options for symptomatic relief [2]. Supply Assurance - The company has prioritized the supply of these influenza-related medications to ensure they meet market demand effectively [2].

Group 1: China Construction - The total new contracts signed by China Construction from January to October reached 3.61 trillion yuan, representing a year-on-year increase of 1% [1] Group 2: Changyuan Power - Changyuan Power's subsidiary received approval for the 100MW wind power project in Songzi, Hubei [2] Group 3: China Metallurgical Group - China Metallurgical Group reported a total new contract amount of 845.07 billion yuan from January to October, a decrease of 11.8% year-on-year, while overseas contracts increased by 7.3% to 71.16 billion yuan [4] Group 4: Shapuaisi - Shapuaisi received approval for clinical trials of deoxycorticosterone ketone solution, intended for use during cataract surgery [5] Group 5: Jianfeng Group - Jianfeng Group's subsidiary received approval for clinical trials of a new drug for treating advanced non-squamous non-small cell lung cancer [7] Group 6: Chongqing Steel - Chongqing Steel announced the resignation of its president Meng Wenwang due to work adjustments [8] Group 7: Tianma Technology - Tianma Technology reported an output of approximately 1732.99 tons of eel in October, with a total output of about 15218.73 tons from January to October [10] Group 8: Qingyuan Co. - Qingyuan Co.'s controlling shareholder reduced holdings of convertible bonds by 685,400 units, accounting for 13.71% of the total issuance [11] Group 9: Spring Airlines - Spring Airlines reported a passenger turnover of 506,200.49 million kilometers in October, a year-on-year increase of 20.06% [12] Group 10: China Merchants Port - China Merchants Port reported a total container volume of 17.1714 million TEUs from January to October, a year-on-year increase of 5.1% [13] Group 11: Yangdian Technology - Yangdian Technology announced a change in control following a share transfer [15] Group 12: Wanfu Biology - Wanfu Biology decided to postpone the implementation of its Knowledge City production base project [16] Group 13: Iwu Biology - Iwu Biology terminated the research project for a specific drug, which will reduce its 2025 net profit by approximately 333.79 million yuan [17] Group 14: Hainan Rubber - Hainan Rubber received an insurance payout of 22.9241 million yuan due to revenue loss from rubber price fluctuations [19] Group 15: Xinjiang Tianye - Xinjiang Tianye plans to establish a joint venture with Tianchi Energy to develop coal chemical projects [20] Group 16: China Coal Energy - China Coal Energy's executive director and president Zhao Rongzhe resigned due to reaching retirement age [22] Group 17: Huading Co. - Huading Co. received approval for a stock issuance to specific investors from the Shanghai Stock Exchange [24] Group 18: Zhongmu Co. - Zhongmu Co. decided to waive its right of first refusal for a 4.04% stake in a subsidiary [25] Group 19: Tianlong Co. - Tianlong Co. reported that its subsidiary's stock issuance was approved by the Beijing Stock Exchange [26] Group 20: Hualan Co. - Hualan Co.'s subsidiary plans to invest 20 million yuan in a biotechnology company [27] Group 21: Haichen Pharmaceutical - Haichen Pharmaceutical received a drug registration certificate for a new injection [28] Group 22: Aier Eye Hospital - Aier Eye Hospital plans to invest 300 million yuan in wealth management products [29] Group 23: Xiamen Engineering Machinery - Xiamen Engineering Machinery announced a planned share reduction by a major shareholder [30] Group 24: Guotai Group - Guotai Group successfully acquired 100% of a mining technology company for 110.1 million yuan [31] Group 25: Wanfeng Aowei - Wanfeng Aowei reached a settlement regarding an arbitration matter with a subsidiary [32] Group 26: Taihe Technology - Taihe Technology is undergoing technical upgrades for its ethylene carbonate project [33] Group 27: Renhe Pharmaceutical - Renhe Pharmaceutical's controlling shareholder plans to reduce holdings by 0.21% [34] Group 28: Changshu Bank - Changshu Bank's second-largest shareholder increased its stake to 3.98% [35] Group 29: Overseas Chinese Town A - Overseas Chinese Town A reported a 57% decrease in contract sales in October [36] Group 30: Canadian Solar - Canadian Solar's controlling shareholder expects total revenue of 1.3 to 1.5 billion USD in Q4 2025 [38] Group 31: Zhonggong Education - Zhonggong Education's controlling shareholder's shares will be auctioned due to a loan dispute [40] Group 32: Aikexibo - Aikexibo's shareholders plan to reduce their holdings by up to 3% [42] Group 33: Wanhua Chemical - Wanhua Chemical's shareholder plans to reduce holdings by up to 0.5% [44] Group 34: Jujie Microfiber - Jujie Microfiber's controlling shareholder plans to reduce holdings by up to 2% [45] Group 35: Wangsu Technology - Wangsu Technology's shareholder plans to reduce holdings by up to 1% [46] Group 36: Tianli Lithium Energy - Tianli Lithium Energy received a patent for lithium-ion battery materials [47] Group 37: Heshun Electric - Heshun Electric won a 40 million yuan project for energy storage services [49] Group 38: Changchun High-tech - Changchun High-tech's subsidiary received FDA approval for a clinical trial of a new drug [51] Group 39: Dongrui Co. - Dongrui Co. received an additional export quota for live pigs to Hong Kong [52] Group 40: Zhongwei Co. - Zhongwei Co. set the H-share issuance price at 34 HKD per share [53] Group 41: Fospower Technology - Fospower Technology plans to invest in a lithium sulfide project with partners [54]

Core Viewpoint - The controlling shareholder, Renhe (Group) Development Co., Ltd., plans to reduce its stake in Renhe Pharmaceutical Co., Ltd. due to its own development needs, intending to sell up to 3,000,000 shares, which represents 0.2143% of the company's total share capital [2][5]. Shareholder Holding Situation - As of the announcement date, Renhe (Group) Development Co., Ltd. holds 325,299,386 shares of the company, accounting for 23.2367% of the total shares [2]. Reduction Plan Details - The reduction plan will be executed within three months starting from 15 trading days after the announcement date, through centralized bidding or block trading methods [2][3]. - The number of shares to be reduced will be adjusted if there are changes in the company's capital structure, such as stock dividends or capital increases, but the proportion of the total share capital will remain unchanged [2][4]. Compliance and Commitments - Renhe (Group) Development Co., Ltd. has fulfilled its previous commitments regarding share trading restrictions, which were in place for 36 months after the shares became tradable [4][5]. - The current reduction plan does not conflict with any previously disclosed intentions or commitments [5].

Core Points - Renhe Pharmaceutical announced a share reduction plan involving its major shareholder, Renhe (Group) Development Co., Ltd., which currently holds 325,299,386 shares, accounting for 23.2367% of the total shares [2] - The company plans to reduce its holdings by up to 3,000,000 shares, representing a maximum of 0.2143% of the total share capital, within three months starting from 15 trading days after the announcement [2] - Any adjustments to the number of shares to be reduced will be made in the event of corporate actions such as stock dividends, capital increases, or new share issuances, but the percentage of total share capital will remain unchanged [2]

Core Viewpoint - Renhe Pharmaceutical (000650.SZ) announced that its controlling shareholder, Renhe (Group) Development Co., Ltd., plans to reduce its shareholding by up to 3 million shares within three months after the announcement, representing a maximum reduction of 0.2143% of the company's total share capital [1] Summary by Sections - Shareholding Reduction Plan - The controlling shareholder intends to reduce its stake through centralized bidding or block trading [1] - The maximum number of shares to be sold is 3 million [1] - The reduction will occur within three months following the announcement, starting 15 trading days after the disclosure [1]

Group 1 - The core point of the article is that Renhe Pharmaceutical announced a share reduction plan by its controlling shareholder, Renhe Group, intending to reduce up to 3 million shares, which is 0.2143% of the total share capital [1] - The share reduction will take place within three months after a 15 trading day period from the announcement date, using centralized bidding or block trading methods [1] - Any corporate actions such as stock dividends, capital increases, or new share issuances during the reduction period will lead to an adjustment in the number of shares to be reduced, but the percentage of total share capital will remain unchanged [1] Group 2 - For the first half of 2025, Renhe Pharmaceutical's revenue composition shows that 99.25% comes from the pharmaceutical industry, while other businesses account for 0.75% [1] - As of the report date, Renhe Pharmaceutical has a market capitalization of 8.9 billion yuan [1]

Core Viewpoint - Renhe Pharmaceutical (000650.SZ) announced a plan for its parent company, Renhe (Group) Development Co., Ltd., to reduce its shareholding by up to 3,000,000 shares, representing a maximum of 0.2143% of the total share capital within three months after the announcement [1] Summary by Sections - **Share Reduction Plan** - The reduction will be executed through centralized bidding or block trading [1] - The plan will be implemented within three months from the announcement date, starting 15 trading days after the disclosure [1] - **Adjustment Clause** - If any corporate actions such as stock dividends, capital increases, new share issuance, or rights issues occur during the reduction period, the number of shares to be reduced will be adjusted accordingly, while maintaining the same percentage of total share capital [1]

Core Viewpoint - Renhe Pharmaceutical (000650.SZ) announced a plan for its parent company, Renhe (Group) Development Co., Ltd., to reduce its shareholding by up to 3,000,000 shares, representing a maximum of 0.2143% of the total share capital within three months from the announcement date [1] Summary by Sections - **Share Reduction Plan** - The reduction will be executed through centralized bidding or block trading methods [1] - The adjustment of the reduction quantity will occur if there are corporate actions such as stock dividends, capital increases, or new share issuances during the reduction period, but the percentage of total share capital will remain unchanged [1]

证券代码：000650 证券简称：仁和药业 公告编号：2025-043 仁和药业股份有限公司 关于控股股东减持股份预披露的公告 控股股东仁和(集团)发展有限公司向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ●股东持股的基本情况: 截至本公告披露日，仁和(集团)发展有限公司持有公司无限 售条件流通股 325,299,386 股，占公司股份总数的 23.2367%。 ●减持计划的主要内容：仁和(集团)发展有限公司因自身发展需要，拟自本公告披露 之日起 15 个交易日后的 3 个月内，通过集中竞价或大宗交易的方式减持公司股份不超过 3,000,000 股，减持比例不超过公司总股本的 0.2143%。减持计划实施期间，公司若发生送 红股、转增股本、增发新股或配股等股本除权事项的，减持数量将进行相应调整，但减持 股份占公司总股本的比例不变。 仁和药业股份有限公司（以下简称"公司"）于近日收到控股股东仁和（集 团）发展有限公司（以下简称"仁和集团"）出具的《股份减持计划告知函》， 现将有关情况公告如下： ...